WA
PEARW

Whitebox Advisors’s Pear Therapeutics, Inc. Warrant PEARW Stock Holding History

Whitebox Advisors’s Portfolio PEARW Stock Details PEARW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-16,766
Closed -$16K – 601
2021
Q1 		$16K Buy
+16,766
New +$16.3K ﹤0.01% 362

Other funds holding PEARW

RCM
Radcliffe Capital Management Bala Cynwyd, Pennsylvania $1.33B AUM 1.18% 1-Year Est. Return
PSAMP
P. Schoenfeld Asset Management (PSAM) New York $184M AUM 97.09% 1-Year Est. Return
AC
Aristeia Capital Greenwich, Connecticut $4.82B AUM 24.94% 1-Year Est. Return
KCM
Kingstown Capital Management New York $30.4M AUM 3.71% 1-Year Est. Return
SC
Sculptor Capital New York $9.61B AUM 27.49% 1-Year Est. Return
KC
Kepos Capital New York $61.3M AUM 12.13% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.71B AUM 81.93% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
AGC
Angelo Gordon & Co New York $1.06B AUM 47.95% 1-Year Est. Return
PC
Periscope Capital Toronto, Ontario, Canada $902M AUM 6.51% 1-Year Est. Return

Whitebox Advisors's PEARW Position: Q2 2021 in Review

Whitebox Advisors sold out of Pear Therapeutics, Inc. Warrant (PEARW) in Q2 2021, closing a stake of 16,766 shares — an estimated $16K sold.

Whitebox Advisors first reported a position in PEARW in Q1 2021 and held it in 1 quarter. The position peaked at $16K in Q1 2021. 45 funds tracked by Wall St. Rank hold PEARW as of Q2 2021.

  • Whitebox Advisors reported no remaining Pear Therapeutics, Inc. Warrant position as of Q2 2021 after selling out during the quarter.
  • Whitebox Advisors sold 16,766 Pear Therapeutics, Inc. Warrant shares in Q2 2021, an estimated $16K.
  • Whitebox Advisors first reported a position in Pear Therapeutics, Inc. Warrant in Q1 2021 and held it in 1 quarter.
  • Whitebox Advisors's Pear Therapeutics, Inc. Warrant position peaked at $16K in Q1 2021.
  • 45 funds tracked by Wall St. Rank held Pear Therapeutics, Inc. Warrant as of Q2 2021.

Based on Whitebox Advisors's 13F filing for Q2 2021, filed 16 Aug 2021.